key: cord-1053042-vcmhhecw
authors: Barkas, Fotios; Christaki, Eirini; Liberopoulos, Evangelos; Kosmidou, Maria; Milionis, Haralampos
title: Anakinra in COVID-19: A step closer to the cure
date: 2021-11-11
journal: Eur J Intern Med
DOI: 10.1016/j.ejim.2021.11.005
sha: dfbaad62e6ed1f0818210c8347f62811fb768a8d
doc_id: 1053042
cord_uid: vcmhhecw

nan

Acute respiratory distress syndrome and cytokine release syndrome are the major 1 complications of coronavirus disease 2019 (COVID-19) associated with increased 2 mortality risk [1] . Apart from dexamethasone and probably tocilizumab in critically ill 3 patients, there are no well-established effective therapies to treat SARS-CoV-2 4 infection [2, 3] . Considering the noticed shortage of intensive care unit (ICU) beds 5 and consequently the increased burden in medical wards [4] , identifying additional 6 therapeutic modalities to improve adverse outcomes and prevent ICU admission and 7 death in this population remains a public health emergency.

In this setting, anakinra has been proved an appealing therapeutic option for 9 the management of coronavirus disease 2019 (COVID-19) [5] . A meta-analysis of 10 four observational studies (n=184) provided early evidence indicating that the 11 administration of anakinra was safe and could be associated with a clinical benefit in 12 patients with COVID-19 [6] . This argument was further strengthened by a subsequent head-to-head randomized clinical trial (RCT) comparing anakinra with tocilizumab 1 available yet, an analysis of three observational studies (n=237) indicated that 2 anakinra might be superior to tocilizumab in terms of COVID-19 death prevention, 3 since the former was associated with a decreased mortality risk by 40% (relative risk: 4 0.60, 95% CI: 0.36-0.98, I 2 =0%) [13] . However, the small sample size and design 5 flaws of the included studies comprise notable limitations to reach safe conclusions. 6 Considering that vaccination rates fall behind what was expected, encouraging 7 results from RCTs promote continuously testing for efficacious, safe and tolerable 8 therapeutic interventions in COVID-19. 

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2

Admitted to ICUs of the Lombardy Region

A 4 living WHO guideline on drugs for covid-19

Tocilizumab in COVID-19: some clarity amid controversy

COVID-19 and Italy: what next?

Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a 11 systematic review and meta-analysis. Rheumatology (Oxford)

Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort 14 studies

Early treatment of COVID-19 with anakinra guided by soluble urokinase 17 plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 18 trial

Soluble urokinase plasminogen activator receptor (suPAR) as an early 21 predictor of severe respiratory failure in patients with COVID-19 pneumonia

COVID-19-1 associated hyperinflammation and escalation of patient care: a retrospective 2 longitudinal cohort study

Effect of anakinra on mortality in patients with COVID-19: a systematic review and 5 patient-level meta-analysis. The Lancet Rheumatology

Tocilizumab in patients admitted to hospital with COVID-19 7 (RECOVERY): a randomised, controlled, open-label, platform trial

COVID-19) Update: FDA Authorizes Drug for Treatment of 10

Anakinra or tocilizumab for prevention 13 of COVID-19 death? A big dilemma